GPER1 and breast cancer: In this sense, experiments carried out by our group on breast cancer cell lines support that continuous pharmacological blockade of classical ERs leads to the overexpression of GPER-1 (non-classical ER) as an alternative pathway to promote proliferation (Molina et al., 2020).